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Hyaluronidase has been used over many decades as an adjunct to local anaesthetic solution to improve the speed of onset
of eye blocks and to provide better akinesia and analgesia. With the evolution of modern eye surgery techniques, fast onset
and akinesia are not essential requirements anymore. The assumption that the addition of hyaluronidase to local anaesthetic
injections confers better analgesia for the patient needs to be examined. There has been no recent systematic review to
provide evidence that hyaluronidase actually improves analgesia.
Objectives
To ascertain if adding hyaluronidase to local anaesthetic solutions for use in ophthalmic anaesthesia in adults results in a
reduction of perceived pain during the operation and to assess harms, participant and surgical satisfaction, and economic
impact.
Search methods
We carried out systematic searches in Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and
four other databases in June 2017. We searched the trial registers at www.ISRCTN.com, ClinicalTrials.gov and
www.clinicaltrialsregister.eu for relevant trials. We imposed no language restrictions.
Selection criteria
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We included randomized controlled trials (RCTs) that evaluated the effect of hyaluronidase on pain experienced by adults
during intraocular surgery using a rating scale.
Data collection and analysis
Two review authors (HR and KA) independently extracted data and assessed methodological quality using standard
procedures as expected by Cochrane.
Main results
We included seven trials involving 500 participants that studied the effect of hyaluronidase on intraoperative pain. Four of
the seven trials with 289 participants reported the primary outcome in a dichotomous manner, and we proceeded to meta-
analyse the findings which showed a moderate heterogeneity that could not be explained (I2 = 41% ). The pooled risk ratio
(RR) for these four trials was 0.83 with the 95% confidence interval ranging from 0.48 to 1.42. The reduction in intraoperative
pain scores in the hyaluronidase group were not statistically significant. Among the three trials that reported the primary
outcome in a continuous manner, the presence of missing data made it difficult to conduct a meta-analysis. To further
explore the data, we imputed standard deviations for the other studies from another included RCT (Sedghipour 2012).
However, this resulted in substantial heterogeneity between study estimates (I² = 76% ). The lack of reported relevant data in
two of the three remaining trials made it difficult to assess the direction of effect in a clinical setting.
Overall, there was no statistical difference regarding the intraoperative reduction of pain scores between the hyaluronidase
and control group. All seven included trials had a low risk of bias.
According to GRADE, we found the quality of evidence was low and downgraded the trials for serious risk of inconsistency
and imprecision. Therefore, the results should be analysed with caution.
Participant satisfaction scores were significantly higher in the hyaluronidase group in two high quality trials with 122
participants. Surgical satisfaction was also superior in two of three high quality trials involving 141 participants. According to
GRADE, the quality of evidence was moderate for participant and surgical satisfaction as the trials were downgraded for
imprecision due to the small sample sizes. The risk of bias in these trials was low.
There was no reported harm due to the addition of hyaluronidase in any of the studies. No study reported on the cost of
hyaluronidase in the context of eye surgery.
Authors' conclusions
The effects of adding hyaluronidase to local anaesthetic fluid on pain outcomes in people undergoing eye surgery are
uncertain due to the low quality of evidence available. A well designed RCT is required to address inconsistency and
imprecision among the studies and to determine the benefit of hyaluronidase to improve analgesia during eye surgery.
Participant and surgical satisfaction is higher with hyaluronidase compared to the control groups, as demonstrated in
moderate quality studies. There was no harm attributed to the use of hyaluronidase in any of the studies. Considering that
harm was only rarely defined as an outcome measure, and the overall small number of participants, conclusions cannot be
drawn about the incidence of harmful effects of hyaluronidase. None of the studies undertook cost calculations with regards
to use of hyaluronidase in local anaesthetic eye blocks.
Plain language summary
Addition of hyaluronidase to local anaesthetic eye blocks to reduce pain during eye surgery in adults.
Review question 
We reviewed the evidence on the effectiveness of adding hyaluronidase to local anaesthetic eye block solutions (a numbing
medicine injected into the eye to block nerves) to reduce pain and increase participant and surgical satisfaction during eye
surgery in adults. We also looked for reports on side effects and cost.
Background
Hyaluronidase is an enzyme (a protein that regulates a chemical reaction in the body) that helps the spread of local
anaesthetic through the tissues around the eye. It is widely used as an additive to local anaesthetic eye blocks to give more
rapid onset of anaesthesia and reduce or block movement of the eye (called akinesia). With modern eye surgery techniques,
fast onset and akinesia are no longer essential requirements, and often surgery can be undertaken pain-free with topical (on
the surface of the eye) anaesthesia alone. Hyaluronidase has been associated with infrequent side effects. Therefore, the
use of hyaluronidase needs to be justified, which was the aim of this review.
Search date
The review is current to 30 June 2017.
Study characteristics
We included seven randomized controlled trials (clinical studies where people are randomly put into one of two or more
treatment groups) in our review. These involved 500 adults undergoing eye surgery under local anaesthesia. We looked at
any additional effect of adding hyaluronidase to local anaesthetic on the pain experienced during eye surgery. We also
looked at participant and surgical satisfaction scores and if any harms were reported after using hyaluronidase in the
injection solution. None of the studies reported on costs.
Key results
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Of the seven included trials, we pooled the results of four trials (289 participants) as the results were reported in a similar
manner. They found that addition of hyaluronidase did not significantly reduce pain during surgery. Among the three
remaining trials (211 participants) lack of data reporting in two trials made it difficult to pool the results. The overall result of
looking at all these trials together suggests there was no significant reduction of pain with using hyaluronidase in eye nerve
blocks.
We found moderate quality evidence from two trials (122 participants) to suggest that addition of hyaluronidase increased
participant satisfaction scores. Three studies involving 141 participants looked at surgical satisfaction, which was reported as
superior with hyaluronidase in the two larger studies and not significantly different in one small study (19 participants). None
of the included studies reported any harmful effects of hyaluronidase.
Quality of evidence
The included trials that reported on pain during surgery were at low risk for bias. The overall quality of evidence was low
because of variations in the effect on pain reduction. We contacted all trial authors to request more information on the trials,
but the data were not available.
Moderate quality studies reported greater participant and surgical satisfaction with hyaluronidase.
Analgesia alone does not take into account the full spectrum of the beneficial effects of hyaluronidase. Patient comfort with
the eye surgery is also likely to be improved by a speedy onset and reduced eye movements due to hyaluronidase.
Background 
Description of the condition
Local anaesthesia for ophthalmic surgery can be provided by regional injection block or topical anaesthesia alone. The most
frequently used anaesthetic injections are retrobulbar, peribulbar and sub-Tenon's block.
During a local anaesthetic injection for ophthalmic surgery, the objective is to deliver local anaesthetic fluid to the
sensory and motor nerve fibres in the orbit. There is a large variation of techniques, anaesthetic mixtures and
instruments in use to achieve this. Some of these techniques have been compared in Cochrane Reviews; for
example, peribulbar versus retrobulbar block (Alhassan 2015), and topical anaesthesia alone versus sub-Tenon's block
(Guay 2015). Schein 2000 undertook a comprehensive systematic review of anaesthetic interventions.
Unfortunately, there is always a proportion of blocks that fail to provide adequate analgesia or akinesia. To improve the
quality of the anaesthetic block, various adjuncts to the local anaesthetic fluid have been introduced.
Description of the intervention
Atkinson 1949 first described the addition of hyaluronidase to local anaesthetic fluid with the intention of improving the speed
of onset of analgesia and akinesia. Subsequently, hyaluronidase has commonly been added to local anaesthetic injection
fluid for this purpose.
How the intervention might work
For any local anaesthetic block to work, the local anaesthetic fluid needs to spread through the orbital cavity to
reach the relevant motor and sensor fibres. A complex system of connective tissue membranes divides the orbital
space, thereby impeding the spread of local anaesthetic fluid (Koornneef 1988).
Buhren 2016 described the molecular mechanisms of how hyaluronidase spreads through this connective tissue barrier, in
the most recent review on this topic. The main components of connective tissue are the fibrous proteins collagen and elastin
as well as proteoglycans located in the extracellular matrix. Glycosamine-glycans attach to proteoglycans in a characteristic
manner giving the connective tissue its viscoelastic properties. The most common glycosamine-glycan is hyaluronic acid, it is
a linear glycosaminoglycan disaccharide composed of alternating units of N-acetyl-D-glucosamine and D-glucuronic acid via
alternating ß(1-4) and ß(1-3) glycosidic bonds. Hyaluronidase (hyaluronoglucosaminidase) is an enzyme that facilitates the
spread of local anaesthetic fluid through connective tissue by degrading hyaluronic acid into smaller fragments and
hydrolyzing the disaccharides at hexosaminidic ß(1-4) linkages.
Meyer 1934 first extracted hyaluronidase. Preparations contain purified ovine testicular hyaluronidase as a
dehydrated sterilized solid for reconstitution before use. Brand names of animal-derived hyaluronidase include
Hydase, Vitrase, Amphadase, Wydase and Hyalase. Apart from a preparation of ovine testicular hyaluronidase, a
recombinant human hyaluronidase is also available as Hylenex. It is produced by genetically engineered Chinese
hamster ovary cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (Hylenex®
Prescribing Information 2016). The exact chemical structure of this enzyme is unknown. The approximate molecular
weight is 61,000 daltons (Borders 1968).
Hyaluronidase also alters the pH of a local anaesthetic due to the presence of phosphate buffers within the
preparation. The pH of plain bupivacaine solution is changed from 5.3 to 6.3 following the addition of hyaluronidase,
and it may maintain local anaesthetic solubility during the process of alkalinization (Roberts 1993).¬This alkalinization may
also explain any improved anaesthesia and akinesia.¬
A reduction in time to onset of surgical anaesthesia is considered desirable to facilitate patient throughput. The
action of hyaluronidase may promote rapid onset of anaesthesia and akinesia. The minimum and maximum
effective doses of hyaluronidase are unknown. The doses used range from 0.75 IU/mL to 300 IU/mL (Dempsey 1997).
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Why it is important to do this review
We conducted this systematic review to explore the uncertainty about the benefits of using hyaluronidase in local anaesthetic
mixtures to provide analgesia during eye surgery. There is considerable variation of practice, and the studies in this area
show conflicting results.
Furthermore, the use of hyaluronidase increases the cost of the anaesthetic and has been associated with adverse allergic
reactions in a small number of cases. For example, Kempeneers 1992, described five people who developed an orbital
pseudotumour as a complication of retrobulbar anaesthesia. Allergic reactions can range from local reactions to
anaphylactic (systemic allergy) shock. When hyaluronidase is added to a local anaesthetic agent, the wider spread of
the local anaesthetic solution also increases its absorption and removal in the bloodstream. This shortens the duration
of action of the local anaesthetic and tends to increase the incidence of systemic reactions. Some hyaluronidase
products contain bovine ingredients, and due to the theoretical concerns about transmissible spongiform
encephalopathies, the World Health Organization (WHO) issued guidelines regarding the use of bovine materials in the
manufacture of biological and pharmaceutical products (WHO 2010).
The absence of hyaluronidase in ophthalmic regional blockade has also been associated with adverse events. An
interruption in hyaluronidase supply was associated with a cluster of postoperative diplopia (double vision) Brown 1999. It
was postulated that the absence of hyaluronidase caused the local anaesthetic to loculate in close proximity to the
extraocular muscles and cause clinically significant myotoxicity. When hyaluronidase was unavailable once again in 2000,
Brown 2001 published a repeated cluster of diplopia cases. The omission of hyaluronidase in local anaesthesia
fluid leads to clinically important rises in intraocular pressure. This is thought to be due to the decreased removal
and dispersal of local anaesthetic fluid from the periocular compartment (Dempsey 1997).
Therefore, use of hyaluronidase must be justified, and data must be available for clinicians and patients to make an informed
decision regarding the efficacy of hyaluronidase addition. The results of this review should allow justification (or not) for the
use of adjuvant hyaluronidase to improve the quality of anaesthesia and analgesia.
Objectives 
To ascertain if adding hyaluronidase to local anaesthetic solutions for use in ophthalmic anaesthesia in adults results in a
reduction of perceived pain during the operation and to assess harms, participant and surgical satisfaction and economic
impact.
(See Differences between protocol and review).
Methods 
Criteria for considering studies for this review 
Types of studies 
We included:
Randomized controlled trials (RCTs) and quasi-randomized controlled clinical trials either published or unpublished;1.
Studies if they compared equal volumes and concentrations of local anaesthetic with and without adjuvant hyaluronidase2.
administered with the injection;
Studies when other adjuvants such as adrenaline were used, only if the adjuvant was present in both the control and3.
hyaluronidase intervention;
Types of participants 
We included:
Adults (aged 18 years and older) presenting for ophthalmic surgery under ophthalmic anaesthetic block;1.
Participants receiving sub-Tenon's, peribulbar, retrobulbar or other types of local anaesthetic;2.
Participants receiving sedation but documented this fact;3.
We excluded:
Participants receiving adnexal surgery and any other eye surgery that was not intraocular;1.
Participants who received general anaesthesia;2.
Types of interventions 
Ophthalmic local anaesthetic blocks comparing adjuvant hyaluronidase to an otherwise equal anaesthetic and surgery
without hyaluronidase.
We considered any dose of hyaluronidase in the intervention group and any dose or type of local anaesthetic agent.
We included studies that used any number of injections to anaesthetise the eye if the number of injections was equal in the
treatment and control groups.
Types of outcome measures 
Primary outcomes
Intraoperative pain, as measured by analogue rating scales. We excluded studies that reported pain, but did not measure1.
pain formally using analogue rating scales, as they did not provide sufficiently useful information on the outcome. We
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excluded studies if they reported that 'supplementary injections' were primarily given to achieve akinesia, for example, if a
certain immobility score was not reached.
(See Differences between protocol and review).
Secondary outcomes
Incidence of harm (reported as a narrative).1.
Participant and surgical satisfaction, as documented by scoring systems.2.
Economic outcomes or cost calculations (reported as a narrative).3.
Search methods for identification of studies 
Electronic searches 
We carried out systematic searches in:
The Cochrane Central Register of Controlled Trials( CENTRAL, 2007 Issue 6; Appendix 1);1.
Ovid MEDLINE (1946 to 30 June 2017; Appendix 2);2.
Ovid Embase (1947 to 30 June 2017; Appendix 3);3.
Web of Science (1900 to 30 June 2017; Appendix 4);4.
Scopus (1823 to 30 June 2017; Appendix 5);5.
CINAHL Plus (EBSCOhost, 1937 to 30 June 2017; Appendix 6);6.
LILACS (1982 to 30 June 2017; Appendix 7);7.
We broke down our research question into four key searchable concepts: " Eye," "Surgery," " Local Anaesthesia" and
"Hyaluronidase".This strategy ensured that we retrieved studies on eye surgery where local anaesthesia was applied along
with hyaluronidase. We conducted searches for each concept using free text terms and MeSH terms wherever possible.
When we carried out free text searches, we applied synonyms, derivative forms and singular/plural forms for each concept.
Detailed search steps are documented in the 'Appendices'.
We applied no language restrictions.
Searching other resources 
We searched the reference lists of all eligible trials and reviews and used any trials that fit the inclusion criteria.
We searched the registers at www.controlled-trials.com, www.ISRCTN.com and www.clinicaltrialsregister.eu for relevant
trials.
We contacted specialists in the field, authors of the included trials and pharmaceutical manufacturers for any unpublished
data.
The search of these other resources was completed by 30 June 2017.
Data collection and analysis 
Selection of studies 
Two review authors (KA and HR) independently reviewed the trials identified from the search strategy, removed duplicates
and documented the reason for each trial being excluded (see Characteristics of excluded studies table). We resolved any
disagreements with the studies by input from a third review author CB). We presented information regarding methods,
participants, setting, interventions and outcomes in the Characteristics of included studies table. Where studies had multiple
publications, we planned to collate the reports of the same study so that each study, rather than each report, was the unit of
interest for the review, and such studies had a single identifier with multiple references. (See Differences between protocol
and review).
Data extraction and management 
Two review authors (KA and HR) independently extracted and collected data on a paper form. After initial piloting this form
was assessed and agreed for usability. A copy of this form is in Appendix 8. We (KA and HR) resolved any discrepancies in
data extracted by discussion with a third review author (CB) as a final arbiter. In the case of additional information being
required, HR or KA contacted the authors of the relevant trial.
Assessment of risk of bias in included studies
To assess the risk of bias, two review authors (KA and HR) independently assessed the studies included in the review
according to the criteria described by Higgins 2011. We assessed the following aspects as being at either 'low risk', 'high risk'
or 'unclear risk' of bias. We assessed the risk of bias for the following components of each trial.
Random sequence generation (selection bias).1.
Allocation concealment (selection bias).2.
Masking of participants and personnel (performance bias).3.
Masking of outcome assessment (detection bias).4.
Incomplete outcome data (attrition bias).5.
Selective reporting (reporting bias).6.
Other bias.7.
We included a 'Risk of bias' table as part of the Characteristics of included studies table based on Cochrane's tool for
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assessing the risk of bias, from the Cochrane Handbook for Systematic Reviews of Interventions (Chapter 8:Higgins 2011).
See Appendix 8 (data collection form) and Appendix 10 ('Risk of bias' table).
Measures of treatment effect
Intraoperative pain
We noted intraoperative pain measured using visual analogue scales (VAS) or verbal rating scales (VRS) when available
and interpreted them as continuous data. We used the greatest intraoperative score reported. We planned to use the
standardized mean difference (SMD) as an effect measure and 95% confidence intervals (CIs) to allow for the fact that
different studies might have used different scales. However, because the only studies detected used the same scaling
method, there was no need to use the SMD. If authors documented non-normality of their data, we extracted medians and
interquartile ranges and collated this information. (See Differences between protocol and review).
In the case of absolute numbers of participants experiencing pain where a rating scale was used but reported in a
dichotomous manner (data as pain or no pain), we used risk ratios (RR) with 95% CI as a measure of effect. We collated
this information and reported it. While there was evidence of moderate heterogeneity (I2 = 41%) we presented a meta-
analysis but urge caution interpreting this.
To avoid multiplicity, we restricted meta-analyses to the primary outcomes but this would not be at the cost of presenting the
totality of evidence should there be more RCTs providing information with regards to adverse effects.
Incidence of harm
We would have reported adverse events due to the use of hyaluronidase (e.g. allergic reactions) as a narrative, but as
expected, there were no reports of such adverse events, probably because of their rarity and the relatively small number of
participants in each trial.
Participant and surgical satisfaction
We reported participant and surgical satisfaction scores narratively. We would also have noted as narrative if other validated
tools had been used.
Economic outcomes or cost calculation
We planned to report economic outcomes or cost calculations narratively.
Unit of analysis issues 
We anticipated that most trials would involve one eye per participant, and even if both eyes were included, our outcomes
were primarily measured at the participant rather than eye level. It was very unlikely that both eyes were operated on
simultaneously with different anaesthetic procedures. (See Differences between protocol and review).
Dealing with missing data
We contacted authors and asked them to provide missing data. We imposed a time limit of two months and follow-up on one
occasion. Irrespective of the type of data, we reported dropout rates in the 'Risk of bias' tables within the Characteristics of
included studies table and noted whether or not authors had compared characteristics of participants who had complete data
sets against those that did not. We investigated studies that had missing data, whether or not imputing for missing cases
impacted greatly on the interpretation of findings. We attempted to impute the data, but the values obtained would not be
consistently reflected within the trials due to the variation in sample size.
Assessment of heterogeneity 
We assessed all studies for clinical and methodological heterogeneity. We examined the I2 statistic and it's 95% CI to assess
inconsistency between studies as recommended by the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We used the thresholds advised by Higgins 2011, for the interpretation of the I2 statistic. We found
substantial inconsistency in our primary outcome when assessed as a continuous score (I2 = 76%) but less when assessed
as a dichotomous measure (I2 =41%). We attempted to investigate causes for this by exploring factors such as the type and
duration of surgery, anaesthetic intervention (hyaluronidase dosage, type and volume of anaesthetic fluid) but the number of
studies contributing to the meta-analysis was small. Despite the heterogeneity, we presented a meta-analysed outcome for
the dichotomized outcome but urge caution in its interpretation.
Assessment of reporting biases
We assessed publication bias and small study effects in a qualitative manner using a funnel plot. We planned to test for
funnel plot asymmetry if there had been a meta-analysis with more than 10 studies included.
Data synthesis
We performed the analysis using Review Manager 5 (RevMan 2014).
While we found some evidence of heterogeneity (for the dichotomous outcome), we meta-analysed results using a random-
effects model as per our original intentions. A random-effects model was chosen because we believe that each trial
estimates an intervention effect that follows a distribution across studies.
Subgroup analysis and investigation of heterogeneity 
We planned no subgroup analyses.
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Sensitivity analysis
We carried out sensitivity analyses to explore the robustness of the results to key methodological decisions that we made in
our review. We examined whether or not excluding studies at risk of bias impacted on our findings, and since we had missing
data, we attempted to impute and examine whether or not analysing intention-to-treat data differed considerably from the
available case meta-analysis.
GRADE assessment of quality of evidence
We adopted the GRADE system postprotocol (Rüschen 2013) to rate the quality of evidence for each outcome (Guyatt
2011). GRADE assessment classifies the quality of evidence into four categories; high, moderate, low and very low. The
overall assessment considers the study design, risk of bias, imprecision, inconsistency, indirectness, publication bias, large
effect size, dose-response effect and presence of confounding factors to rate the evidence. We applied the principles of
GRADE to assess the quality of evidence specific to each outcome in our review.
Intraoperative pain, as measured by analogue rating scales.1.
Incidence of harm.2.
Participant and surgical satisfaction, as documented by scoring systems.3.
Economic outcomes or cost calculations.4.
The GRADE software from GRADEpro GDT generated the 'Summary of findings' table. The GRADE approach ensures the
confidence which one can have in the estimate of effect from the outcomes being assessed in the included studies.
(See Differences between protocol and review).
Results 
Description of studies 
See Characteristics of included studies and Characteristics of excluded studies tables.
Results of the search
See Figure 1 for the study flow diagram.
We identified 942 references after removal of duplicates. Two review authors (HR and KA) independently
read and analysed the abstracts of all references and if needed, full papers. We excluded 779 references as
clearly irrelevant to the review. We obtained the full papers for the remaining 163 references and again
analysed them independently. We identified 18 trials, and 11 trials were further excluded for reasons
documented in the 'Characteristics of excluded studies' table. The review includes seven trials.
Included studies
Design
We included seven RCTs published from 1995 to 2012 with 500 participants (Bowman 1997; Brydon 1995; Khandwala 2008;
Remy 2008; Rowley 2000; Sedghipour 2012; Shiroma 2002). One study was published in Portuguese and
translated into English (Shiroma 2002).
Characteristics of study population
The review included 500 participants.The participants were adults (aged 18 years or older) presenting for ophthalmic surgery
undergoing a retrobulbar, peribulbar or sub-Tenon block. The mean age in the studies ranged from 66 to 77 years. Studies
were balanced with regards to gender.
Setting
Four studies were conducted in the UK (Bowman 1997; Brydon 1995; Khandwala 2008; Rowley 2000). The remaining
three studies were based in Germany (Remy 2008), Brazil (Shiroma 2002), and Iran (Sedghipour 2012).
Intervention
The seven trials studied the effect of adding hyaluronidase to a local anaesthetic mixture with the primary outcome measure
of reduction of intraoperative pain. The participants were divided into a treatment group (hyaluronidase) and a control group
(no hyaluronidase). The doses of hyaluronidase used ranged from 15 IU/mL to 150 IU/mL.
All seven trials assessed pain objectively using either the VAS or the VRS and compared a group with
hyaluronidase to a group without hyaluronidase (Bowman 1997; Brydon 1995; Khandwala 2008; Remy 2008; Rowley 2000; 
Sedghipour 2012; Shiroma 2002).
One trial included three arms in their study looking at effects of no hyaluronidase and effects of hyaluronidase at 50
IU/mL and 150 IU/mL (Brydon 1995). We combined the results of the groups with different doses of hyaluronidase and
compared them with the no hyaluronidase group.
Funding sources
Two trials reported no conflict of interest and received no funding support for the trials (Khandwala 2008; Remy 2008
). There was no clear documentation of reported conflict of interest or funding support from the remaining five trials (Bowman
1997; Brydon 1995; Rowley 2000; Sedghipour 2012; Shiroma 2002).
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We attempted to contact the authors of all the trials for additional data but received no clarification.
For more details about the included trials, see the Characteristics of included studies table.
Excluded studies
We excluded 11 studies after analysis (Berg 2001; Crawford 1994; Guise 1999; House 1991; Johansen 1993; Lange 1989; 
Moharib 2002; Morsman 1992; Ramanathan 1999; Sarvela 1992; Soares 2002).
Three studies reported that "supplementary injections" were primarily given to achieve akinesia, for example, if a
certain immobility score was not reached. Pain during surgery was not assessed or reported specifically.(Crawford 1994; 
House 1991; Soares 2002).
One study did not mask the relevant part of the trial (Morsman 1992).
Four studies did not assess pain or discomfort using a rating scale, and the inclusion criteria were ultimately not met (Berg
2001; Guise 1999; Johansen 1993; Moharib 2002). We excluded these studies because they did not measure the outcome
measure of "pain by rating scale". They reported an unstructured description of pain. This is unlikely to provide useful
information about the levels of pain during the operation.
One study was published as a poster presentation (Ramanathan 1999). We contacted the author for more details about
randomization, masking and results but none was made available.
We excluded one study because there was no randomization, this was not immediately obvious (Lange 1989).
We excluded one study because the relevant part of the study was not randomized and only compared different
concentrations of hyaluronidase (Sarvela 1992).
See Characteristics of excluded studies table.
Awaiting classification
We found no studies awaiting classification.
Ongoing studies
We identified no ongoing studies.
Risk of bias in included studies 
We judged the quality of studies according to the methods described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). Overall, the selected studies were of low risk; however, there was a lack of concise information
in the methodology of randomization and withdrawal description. Please refer to Figure 2 and Figure 3 for a summary of risk
of bias assessment for the selected studies and a 'Risk of bias' graph that represents the studies.
Allocation (selection bias)
All seven included studies reported that allocation was randomized, but only three studies provided any detail
about the method of random allocation (Khandwala 2008; Rowley 2000; Sedghipour 2012). These three studies were at low
risk of allocation bias. The studies used random number tables, stratified lottery system or computer generated
randomization. The remaining four studies were at unclear risk of bias.
With regard to allocation concealment, four of the seven studies used "coded syringes" (Khandwala 2008; Remy 2008; 
Rowley 2000; Sedghipour 2012). We classed these at low risk of bias, but an experienced operator might have recognized
the formation of tiny bubbles in the mixture indicating hyaluronidase content.
Most studies implied that participants, personnel and assessors were unaware of the composition of the anaesthetic solution
because the syringes were coded by an uninvolved third party, but exact details were rarely given.
In this context, only one study used a placebo control, with inactive Hyalase (Remy 2008).
Blinding (performance bias and detection bias)
Five studies were classified as low risk for performance and detection bias (Bowman 1997; Khandwala 2008; Rowley 2000; 
Sedghipour 2012; Shiroma 2002). These studies had described double masking where neither the participant nor the
caregiver was aware of the contents of the syringe. The outcome assessors were also masked, which further reduced the
risk of bias by masking.
Incomplete outcome data (attrition bias)
Withdrawal of participants after randomization was rarely reported in detail.
Six studies were at low risk as there was a description of no withdrawals; therefore, we had more confidence in the
intention-to-treat analysis for these studies (Bowman 1997; Brydon 1995; Remy 2008; Rowley 2000; Sedghipour 2012; 
Shiroma 2002).
Of the included seven studies, one described the withdrawal of participants after randomization (Khandwala 2008). One
participant was withdrawn from the treatment group due to incomplete data. No further details were given. Considering the
low number of participants in this trial (10 in each of two arms) the exclusion may represent bias.
Selective reporting (reporting bias)
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We found all seven studies at low risk of reporting bias. Pain was stated as an outcome measure at the start of the
trials. We did not attempt to obtain research protocols (Bowman 1997; Brydon 1995; Khandwala 2008; Remy 2008; Rowley
2000; Sedghipour 2012; Shiroma 2002).
Other potential sources of bias
We found no other potential sources of bias.
Effects of interventions 
Primary outcomes
1. Intraoperative pain, as measured by analogue rating scales
Seven trials with 500 participants looked at the effect of hyaluronidase on the reduction of intraoperative pain. Four
of these trials with 289 participants reported intraoperative pain in a dichotomous manner (Bowman 1997; RR 0.82, 95% CI
0.38 to 1.75; Brydon 1995; RR 1.00, 95% CI 0.20 to 5.00; Remy 2008; RR 0.47, 95% CI 0.24 to 0.92; Shiroma 2002; RR
1.45, 95% CI 0.70 to 3.00). We calculated the (RR) as a measure of effect. The I2 statistic was 41%, which represents
moderate heterogeneity. We proceeded to meta-analyse the results and found that the pooled RR was 0.83 (95% CI 0.48 to
1.42). Therefore, there was no statistically significant reduction of pain scores in the hyaluronidase group.
Three studies involving 211 participants reported pain objectively using rating scales and presented continuous
data (Khandwala 2008; Rowley 2000; Sedghipour 2012). Sedghipour 2012 described 42 participants in a high
quality study and provided SDs for their data. They found a significant reduction of pain in the hyaluronidase
group (P = 0.04). The other two trials did not report SDs (Khandwala 2008; Rowley 2000). We interchanged the SDs from
Sedghipour 2012, but this resulted in significant heterogeneity among the studies (I²= 76%), so we did not perform a meta-
analysis. See Figure 4 and Figure 5.
Looking at the overall studies taking into account the results of the meta-analysis and the individual studies that reported the
continuous outcome, there was no statistically significant reduction in intraoperative pain with hyaluronidase in the local
anaesthetic mixture. However, this has to be interpreted with caution.
We adopted the GRADEpro method of analysing the quality of evidence and produced Summary of findings table 1. We
found the quality of studies was low. We downgraded the quality of evidence due to concerns regarding inconsistency in the
direction and magnitude of effect across the studies (I2 = 41% and 76%). We looked at the individual studies for factors that
could have contributed to the heterogeneity and found that there was no wide variability between characteristics of
participants, interventions and outcome measures. We tried to establish if the heterogeneity was due to the dose of
hyaluronidase, the volume of injection or number of participants, but there was insufficient data provided to enable a valid
analysis. The level of imprecision was another reason for downgrading the quality of evidence. Only Rowley 2000, provided a
rationale for the selected sample size that would yield the specific effect measure.
Secondary outcomes
1. Incidence of harm
None of the included studies measured or reported the incidence of harm from hyaluronidase.
2. Participant and surgical satisfaction, as documented by scoring systems
Two studies analysing 122 participants looking at participant satisfaction reported that the investigator and participant
assessment scores were significantly higher in the hyaluronidase group (P < 0.05)(Remy 2008; Sedghipour 2012). The
studies assessed satisfaction in different ways so prohibiting meta-analysis Remy 2008 used a five level VAS to assess
participant efficacy and tolerability at the end of surgery and at the final visit, while Sedghipour 2012 captured data as a
dichotomous 'satisfied' or 'unsatisfied'. Using the GRADE system to assess the quality of evidence, we found the studies
were of moderate quality with low risk of bias.
We found three studies involving 141 participants that measured surgical satisfaction scores (Khandwala 2008; Remy 2008; 
Sedghipour 2012). Sedghipour 2012 reported that surgical satisfaction with intraoperative anaesthesia was 85.7% in the
hyaluronidase group compared to 52.5% in the control group (P = 0.02). Remy 2008 reported a P value of less than 0.001 for
surgical satisfaction in the hyaluronidase group. Khandwala 2008 found no difference in the quality of the surgical field
between groups (P = 0.96). These studies assessed surgeon satisfaction as they had assessed participant satisfaction while
Khandwala 2008 simply asked surgeons to rate surgical conditions on a VAS from 0 (worst) to 10 (best). Since each had
assessed satisfaction using a different method, no meta-analysis was conducted. There was low risk of bias with regards to
the method of randomization with Sedghipour 2012, and there was incomplete outcome data reporting with Khandwala 2008.
Overall, we found the quality of evidence with these two studies to be moderate. See Figure 2.
3. Economic outcomes or cost calculations
None of the included studies reported on the economic impact of using hyaluronidase.
Discussion 
The use of hyaluronidase in ophthalmic surgery remains a topic of debate. The perceived advantages of adding
hyaluronidase include shortened time to onset of the block and improved akinesia, and as investigated in this review:
analgesia. The apparent disadvantages of hyaluronidase include the additional cost and possible adverse reactions.
Most modern surgical techniques are no longer essentially dependent on akinesia. Anaesthesia itself is readily provided by
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eye blocks without hyaluronidase. Even topical anaesthesia is often deemed sufficient during routine cataract surgery. We
systematically reviewed the literature on the benefits of hyaluronidase for analgesia in ophthalmic surgery.
Summary of main results
We reviewed evidence from seven RCTs involving 500 participants regarding the reduction of pain during intraocular surgery
by adding hyaluronidase to the local anaesthetic fluid. We found that the reduction of intraoperative pain by hyaluronidase
was not statistically significant. The quality of evidence was low. We assessed the literature in this field as having a low risk
of bias, but we had concerns regarding heterogeneity across the studies. With regards to the outcomes of participant and
surgeon satisfaction, the moderate quality studies show an advantage of using hyaluronidase. (See Summary of findings
table 1).
Overall completeness and applicability of evidence
We are confident that our search strategy obtained all available studies. The results of this review are applicable to all adults
undergoing intraocular surgery who would want to make an informed decision regarding the use of hyaluronidase as an
adjunct in eye blocks to reduce intraoperative pain. We found that the use of hyaluronidase is beneficial in terms of
participant and surgical satisfaction. Such benefit from using hyaluronidase was not statistically significant with regards to
intraoperative reduction of pain.
We consider that most of the authors gave priority to akinesia as an outcome measure over analgesia, probably due to the
perceived importance for the safe conduct of surgery. This priority has now receded as the majority of surgeons can carry out
most operations without depending on fully established akinesia. Profound akinesia will still be necessary for more difficult
operations and training situations. Hyaluronidase may be necessary to achieve akinesia in such situations.
Quality of the evidence
We found the overall quality of evidence to be low due imprecision and inconsistency of the results. There was moderate
heterogeneity (I² = 41%). Therefore, we downgraded the quality of evidence by one level. We looked for possible causes for
the variation such as sample size, dose of hyaluronidase or characteristics of participants but data were sparse.
We found the overall risk of bias in the studies to be low. However, there was an unclear risk with regards to methods of
randomization and concealment in a few studies.
As for imprecision, failure to estimate the sample size needed to make an effect by six of the seven studies led to the quality
of evidence to be downgraded by one level.
Potential biases in the review process
A potential bias arises from the narrow spectrum of the review question: "Does hyaluronidase improve pain control during
eye surgery?" Hyaluronidase is used for a variety of indications. For example, if the speed of onset of anaesthesia is
increased by hyaluronidase and the eye is much more akinetic at the beginning of the operation, participant and surgeon
comfort will also likely be increased. Therefore, the narrow aspect of analgesia alone does not consider the full spectrum of
beneficial effects from hyaluronidase.
This review found only a relatively small number of studies (seven) with a small number of participants (500).
However, can systematic reviews with such sparse data be trusted (Afshari 2017)? During this Cochrane Review, we
adhered to all essential requirements such as publishing a protocol, incorporating risk of bias assessment, searching
for unpublished data and many other review tools as laid out in the Cochrane framework (Higgins 2011).
According to our protocol, we excluded studies that did not assess pain in a structured manner (using rating scales).
Because of this, we excluded unstructured assessments that may have shown results. We consider that results from these
trials would have a high risk of reporting bias and therefore, would not produce a reliable, useful effect.
Lack of reported data also led to certain included trials being excluded from the meta-analysis. We were unable to obtain
clarification about these issues from authors of the included studies.
Readers of this review may be interested in the incidence of adverse effects of hyaluronidase use. Adverse effects such as
allergy to hyaluronidase are extremely rare. None of the trials we analysed reported any adverse events related to
hyaluronidase, but we would like to highlight that our review would not have reliably captured the incidence of very rare
adverse events due to an overall small number of participants.
We have acknowledged and taken into account the inherent methodological limitation of our systematic review and in our
opinion addressed them adequately.
Agreements and disagreements with other studies or reviews
Our findings match that of the review of Schein 2000. Their review reported the same problems with the available literature
that we found. Those are;
very few studies reported data on the effect of hyaluronidase on pain;1.
high levels of inconsistency among the included studies.2.
Schein's review was written in 2000, and despite many additional studies having been published since, there is still no
certainty on the effect of hyaluronidase use for analgesia.
Authors' conclusions 
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Implications for practice 
The requirements for ophthalmic anaesthesia have changed considerably since the early 2000s. Nowadays, the majority of
routine cataract surgery can be conducted pain free under topical anaesthesia alone. Injection blocks are used to provide
more profound analgesia for some people and during some operations. The effects of adding hyaluronidase to local
anaesthetic fluid on pain outcomes in people undergoing eye surgery are uncertain due to the low quality of the available
evidence.
Implications for research 
To reach certainty on the question of hyaluronidase use for intraoperative analgesia, future studies should separate the
various outcome parameters of speed of onset and akinesia from that of analgesia.
The importance of pain control is different for anterior and posterior segment eye surgery. This should be looked at in a well
powered randomized controlled trial.
We found no studies that described the economical impact of using hyaluronidase. In the current climate of financial
restrictions, this information would be very valuable, and any future study should incorporate this aspect.
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We made the following changes to the protocol (Rüschen 2013);
This review included only adults, we therefore stated "adults" in the title.1.
The phrase 'to reduce intraoperative pain' was added to the title to comply with PICO to reflect the review question.2.
Lee Adams was initially a registered author, but gave his agreement to be removed from the authors list at the protocol3.
stage.
We added Kavitha Aravinth as second author.4.
We added Desta Bokre as fourth author.5.
We further stated in the primary objective that when considering studies for inclusion that we excluded studies that did not6.
measure pain with a rating scale because spontaneous reporting of pain by the participant is not likely to produce
reproducible results.
We stated the secondary objectives (incidence of harm, participant and surgical satisfaction and economic outcomes or7.
cost calculations) in the Objectives section.
We stated in the protocol that intraoperative pain would be recorded using (VAS); however, we observed that included8.
studies used either (VAS) or (VRS) to rate pain. As both are accepted and validated tools to measure pain, we analysed
both these methods of measuring pain in the same manner.
We initially proposed to include only studies that described the first eye operation, but during the review process, we found9.
no publication that described if the participants had a first or second eye operation.(See Types of participants and Unit of
analysis issues).
We excluded adnexal surgery and any other eye surgery that was not intraocular. Anaesthetic techniques and surgical10.
interventions for adnexal operations are inherently different from intraocular surgery and produce a very different pain
profile.
We used GRADE-pro to analyse the quality of evidence and to produce a 'Summary of Findings table'.11.
Collation of references: we added the following to the Selection of studies section. "Where studies had multiple12.
publications, we planned to collate the reports of the same study so that each study, rather than each report, was the unit
of interest for the review and such studies had a single identifier with multiple references.
Published notes 
Characteristics of studies
Characteristics of included studies 
Bowman 1997
Methods Parallel group, prospective, masked randomized controlled single centre study in the
UK.
Study dates not stated.
 
Participants 92 adults (extracapsular cataract extraction phacoemulsification and trabeculectomy)
received peribulbar block.
Number of participants: hyaluronidase group; 44 control group ; 48.
Mean age : hyaluronidase group: 72 years; control group : 75 years.
 
Interventions Hyaluronidase group ; lignocaine 2% with adrenaline 1:200,000,
+ bupivacaine 0.5% + hyaluronidase 150 IU/mL.
Control group: lignocaine 2% with adrenaline 1:200,000 + bupivacaine 0.5%.
10 mL peribulbar injection using a standardized technique.
 
Outcomes Akinesia, objective analgesia assessed by surgeon, subjective analgesia assessed by
participant after surgery.
VAS 0 to 10 for subjective and objective pain scores were stratified into a dichotomous
pain/no pain.
 
Notes Conflict of interest and funding sources not documented.
 
Risk of bias table
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Bias Authors' judgement Support for judgement
Random sequence generation
(selection bias)




Unclear risk Masked allocation but no details described
 
Incomplete outcome data (attrition
bias)
Low risk No withdrawals reported.
 
Selective reporting (reporting bias) Low risk All groups were reported on.
 
Blinding of participants and
personnel (performance bias)
Low risk Masking of participants described.
 
Blinding of outcome assessment
(detection bias)
Low risk Double masking described.
 
Brydon 1995
Methods Parallel group, randomized double blind design in the UK.
Study dates were not stated.
 
Participants 60 consecutive adults for elective intra-ocular surgery.
Number of participants: 20 per group. Results for low dose and higher dose were
combined for analysis.
Mean age: hyaluronidase (low dose) group: 74 years; hyaluronidase (higher dose)
group: 73 years; control group: 72 years.
 
Interventions Hyaluronidase (low dose) group: peribulbar block with equal mixture of lignocaine 2%
and bupivacaine 0.75% + hyaluronidase 50 IU/mL.
Hyaluronidase (higher dose) group: peribulbar block with equal mixture of lignocaine
2% and bupivacaine 0.75% + hyaluronidase 150 IU/mL.
Control group: peribulbar block with equal mixture of lignocaine 2% and bupivacaine
0.75%.
No sedation and premedication given.
 
Outcomes Speed of onset, akinesia, analgesia, top-up frequency, incidence of harm.
Analgesia measured by assessing participant's reaction to insertion of superior rectus
suture and by direct questioning during procedure. 3 point scoring system used.
Akinesia was the primary outcome measure.
 
Notes Conflict of interest and funding sources not documented.
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Unclear risk Masked allocation but no details described.
 
Incomplete outcome data (attrition
bias)
Low risk No withdrawals.
 
Selective reporting (reporting bias) Low risk All prespecified outcomes reported on.
 
Blinding of participants and
personnel (performance bias)
Unclear risk "Composition of the local anaesthetic solution was not known to the
anaesthetist", but no further details of masking described.
 
Blinding of outcome assessment
(detection bias)
Low risk Assessor (surgeon) masked.
 
Khandwala 2008
Methods Parallel group, prospective randomized controlled double masked, single centre trial in
Leeds, the UK.
Study dates; not stated.
 
Participants 20 adults undergoing routine cataract surgery.
Data for 1 participant in hyaluronidase group were incomplete and excluded from
analysis. Participants were ASA 1-3.
Number of participants in analysis: hyaluronidase group: 9; control group: 10.
Mean age: hyaluronidase group: (73.8 years; control group: 74 years).
Exclusion criteria; refusal, language problems, history of allergy to amide local
anaesthetics or hyaluronidase or pre-existing extra ocular muscle palsy.
 
Interventions Hyaluronidase group: lignocaine 2% + hyaluronidase 15 IU/mL.
Control group: lignocaine 2%.
Sub-Tenon's block. Total volume of local anaesthesia 5 mL with no premedication
sedation.
 
Outcomes Akinesia, depth of anaesthetic fluid spread on ultrasound, surgical conditions, pain
during operation measured by visual analogue scale (VAS).
SD pain scores unavailable. Attempts to contact authors for more clarification
unsuccessful.
 
Notes Authors declared no conflict of interest and received no funding from private or public
bodies.
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Low risk Coded syringes.
 
Incomplete outcome data (attrition
bias)
Unclear risk 1 participant in treatment group excluded after randomization, due to
incomplete data.
 
Selective reporting (reporting bias) Low risk All outcomes reported on.
 
Blinding of participants and
personnel (performance bias)
Low risk Participants and personnel were masked.
 
Blinding of outcome assessment
(detection bias)
Low risk Assessor masked.
 
Remy 2008
Methods Parallel group, prospective randomized double masked placebo controlled trial with a
multicentre design in Germany.
Study dates: 29 July 2003 to 2 November 2004.
 
Participants 80 adults undergoing elective cataract surgery with retrobulbar block. No participant
dropped out.
Number of participants: hyaluronidase group: 40; control group: 40.
Mean (SD) age: hyaluronidase group: 76 ± 11 years; control group; 74±10 years.
Inclusion criteria; adults aged >18 years, elective surgery, no active ocular disease
and informed consent obtained in written form.
Exclusion criteria; known intolerance to hyaluronidase, pregnancy, lack of co-
operation, history of alcohol or drug abuse, or local anaesthetic complications.
 
Interventions Hyaluronidase group: 5 mL 1% mepivacaine + 75 IU/mL hyaluronidase.
Control group: 5 mL 1% mepivacaine + placebo (special batch of Hyalase without
active ingredient).
 
Outcomes Primary end point; complete akinesia after 5 minutes.
Secondary end points; akinesia at other times, top-up injections, ptosis, time to
anaesthesia, pain (VAS) immediately after surgery and 3 hours postsurgery and
efficacy and tolerability for participant and surgeon. Adverse events recorded. First
pain assessment point, planned before surgery then reported for immediately after
surgery.
 
Notes No conflict or financial interest reported by author.
 
Risk of bias table
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Bias Authors' judgement Support for judgement
Random sequence generation
(selection bias)




Low risk Double masked as per German legal framework.
 
Incomplete outcome data (attrition
bias)
Low risk No participant dropped out.
 
Selective reporting (reporting bias) Low risk All outcome measures were reported on.
 
Blinding of participants and
personnel (performance bias)
Low risk Placebo control, double masked.
 
Blinding of outcome assessment
(detection bias)
Low risk Masked according to federal law.
 
Rowley 2000
Methods Parallel group, randomized double masked controlled trial in 1 centre in UK.
Study dates: not stated.
 
Participants 150 adults for elective cataract surgery with sub-Tenon's block.
Number of participants: hyaluronidase group: 76; control group: 74.
Mean age; in hyaluronidase group; 77.14 years; control group; 76.51 years.
Groups similar in terms of age, sex and proportion of blocks administered by each
investigator.
Exclusion criteria: people with learning difficulties, dementia, profound deafness and
known adverse reaction to lignocaine or hyaluronidase.
 
Interventions Hyaluronidase group: 3 mL 2% lignocaine/adrenaline + hyaluronidase 30 IU/mL.
Control group: 3 mL 2% lignocaine/adrenaline.
 
Outcomes Akinesia, post-injection and immediate postoperative pain. Pain measured using VAS
(0-10 cm).
SD pain scores not available with attempts to obtain more clarification from authors
unsuccessful.
 
Notes Declaration of funding sources and conflict of interest not reported.
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Low risk Masked syringes.
 
Incomplete outcome data (attrition
bias)
Low risk No dropouts.
 
Selective reporting (reporting bias) Low risk All outcomes reported accordingly.
 
Blinding of participants and
personnel (performance bias)
Low risk Masking of participants not described. Masking of personnel (operative
surgeon, independent assistant and nursing staff) was described.
 
Blinding of outcome assessment
(detection bias)
Low risk Double masked design.
 
233 Use of hyaluronidase as an adjunct to local anaesthetic eye blocks to reduce intraoperative pain in adults
16 / 38
Sedghipour 2012
Methods Parallel group, randomized double masked trial in 1 centre in Iran.
Study dates: February 2011 to July 2011.
 
Participants 44 adults initially recruited from a referral eye centre (Nikookari Eye Hospital) to
undergo elective cataract surgery (phacoemulsification) under sub-Tenon block. 2
participants did not meet the criteria and were excluded.
Number of participants: hyaluronidase group: 21; control group: 21.
Mean (SD) ages: hyaluronidase group: 65.62 ± 3.01 years; control group; 67 ± 4.4
years.
Groups comparable for gender and age.
Exclusion criteria: people with deafness and allergy to lidocaine or hyaluronidase.
 
Interventions Hyaluronidase group: 2 mL 2% lidocaine + hyaluronidase 150 IU/mL
Control group: 2 mL 2% lidocaine.
Ampoules were identical in appearance with a printed code (A or B).
Codes disclosed for statistical analysis only at end of study.
 
Outcomes Akinesia, participant and surgical satisfaction with yes/no questions, postoperative
pain via VAS scoring using a standard VAS chart. Participants were given appropriate
explanation on usage of chart.
 
Notes No declaration of funding sources or conflict of interest reported.
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Consecutive numbers assigned to participants on admission by a staff




Low risk Coded syringes.
 
Incomplete outcome data (attrition
bias)
Low risk No exclusions after randomization reported.
 
Selective reporting (reporting bias) Low risk All outcomes reported.
 
Blinding of participants and
personnel (performance bias)
Low risk Masking of participants, personnel by coded syringes.
 
Blinding of outcome assessment
(detection bias)
Low risk Assessor masked by coded syringes.
 
Shiroma 2002
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Methods Randomized double masked study conducted at State University of Campinas -
Unicamp, Brazil.
Study dates: not stated.
 
Participants 57 adults undergoing elective extracapsular cataract extraction on an outpatient basis.
Participant's physical statuses described as ASA 1- 3.
Number of participants: hyaluronidase group: 29; control group: 28.
Sex: 31 men (54.4%); 26 women (45.6%).
Age range (overall): 45- 89 years; mean (SD) overall: 67.73 (± 10.65).
Groups homogeneous in relation to sex, age and physical condition.
Peribulbar injection given as a block by double needle injection with 25x7 mm needle,
administered 4 mL at lower temporal with super-medial inclination of about 15°and 3
mL (nasal-superior). Anaesthetic solution prepared without knowledge of
ophthalmologist who performed the block.
 
Interventions Hyaluronidase group: ropivacaine 1% + hyaluronidase 100 IU/mL.
Control group: ropivacaine 1%.
 
Outcomes Onset time to akinesia, need for supplementary injections and pain assessed by VAS
(0-10).
 
Notes No declaration of funding sources or conflict of interest reported.
 
Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Unclear risk Allocation concealment not described.
 
Incomplete outcome data (attrition
bias)
Low risk No withdrawals documented, all participants included initially were
assessed and reported.
 
Selective reporting (reporting bias) Low risk Primary outcomes reported.
 
Blinding of participants and
personnel (performance bias)
Low risk Masking described in participants and personnel.
 
Blinding of outcome assessment
(detection bias)
Low risk Assessment masked.
 
Footnotes
ASA: American Society of Anesthesiology Classification; SD: standard deviation; VAS: visual analogue scale.
Characteristics of excluded studies 
Berg 2001
Reason for exclusion Pain not assessed formally using a rating scale. Instead, augmentation eye drops
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Reason for exclusion 2 participants in the hyaluronidase group received local anaesthetic drops for pain




Reason for exclusion Pain not formally measured using a rating scale.
 
House 1991




Reason for exclusion Surgeon assessed quality of analgesia and pain, not measured by asking participant.
No formal method of assessing pain described.
 
Lange 1989
Reason for exclusion On further inspection, not a randomized trial.
 
Moharib 2002
Reason for exclusion Adequate pain relief defined as lack of complaint or response from participant. Did not




Reason for exclusion Presence or absence of hyaluronidase not masked.
 
Ramanathan 1999




Reason for exclusion Part one of third study was not randomized. Part two of this study compared two
different concentrations of hyaluronidase only.
 
Soares 2002
Reason for exclusion Intraoperative pain not measured (e.g. by asking participant). It was assumed that the
participants would spontaneously voice their pain during operation. Therefore, study
did not measure any of our stipulated outcomes.
 
Footnotes
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of findings tables
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Patients or population: adults (aged ≥ 18 years) undergoing ophthalmic surgery under local anaesthetic eye blocks.
Setting: hospitals in the UK (4), Germany (1), Brazil (1) and Iran (1).
Intervention: local anaesthetic eye blocks containing hyaluronidase.
Comparison: local anaesthetic eye blocks containing no hyaluronidase.









































3 trials looked at effect of hyaluronidase on reduction
of intraoperative pain measured by rating scales.
Results were reported as continuous data. 2 studies
did not provide the SMD, which measures the effect in
a clinical setting, the results could not be meta-
analysed and hence were reported narratively (Khandwala 2008; 
Rowley 2000). Among the 3 trials covering 211
participants (Khandwala 2008: Mean difference 0.70; Rowley
2000: Mean difference 0.31; Sedghipour 2012: Mean
difference -1.10), only the Sedghipour study with 42
participants, which is a high quality study, showed a
statistically significant (at the 5 % level) reduction in
pain in the hyaluronidase group (P = 0.04). The
remaining 2 studies with 169 participants showed no
statistically significant (at the 5 % level) reduction of
pain intraoperatively with hyaluronidase (Khandwala 2008: P =
0.5; Rowley 2000: n.s). These studies were also of high quality
and low risk of bias. Khandwala and colleagues had an unclear
attrition bias as 1/10 participants in the treatment group was

















Significantly better satisfaction in these well designed
studies with low risk of bias (Remy 2008; Sedghipour 2012). The
studies included 122 participants and showed higher satisfaction
















Surgical satisfaction was reportedly superior with
hyaluronidase in the larger 2 studies (Remy 2008: P < 0.001;
Sedghipour 2012: P = 0.02) and not significantly











None of the included studies reported economic outcomes or cost
calculations
- (0 RCTs) - -
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; n.s: nonstatistically significant; RCT: randomized controlled trial; RR: risk ratio; SMD: standardized
mean difference.
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of
the effect.
Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from
the estimate of effect.
Footnotes
1Downgraded one level due to marked heterogeneity with a calculated I2 > 50%.
2Downgraded one level for imprecision due to wide 95% confidence intervals, reflecting uncertainty in the direction of effect
estimate.
3Downgraded one level for imprecision and inconsistency in measurement, lack of data and small sample size.
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Caption
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figure 3
Caption
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included
studies.
Figure 4 (Analysis 1.1) 
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Forest plot of comparison: 1 Hyaluronidase versus control, outcome: 1.1 Intraoperative pain (measured by analogue rating
scales; reported continuous).
Figure 5 (Analysis 1.2) 
Caption
Forest plot of comparison: 1 Hyaluronidase versus control, outcome: 1.2 Intraoperative pain (measured by analogue rating
scales; reported dichotomous).
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1 eye* or Ophthalm* or ocular 39,485
  cornea* or retin* or scler* or vitre* or iris or pupil or orbit* or chorod* 33,449
3 intraocular or intra-ocular or extraocular or extra-ocular or monocular or oculo* or oculi or optic* 16,808
4 visual* or vision or sight or see* or view* or blind* 380,089
5 glaucoma or conjuncti* or uveitis or macula* or oedema or edema or strabismus or squint or
astigmati* or myopi* or hypermetropia or trachoma
33,656
6 #1 or #2 or #3 or #4 or #5 413,088
7 surg* or operat* 203,926
8 transplant* or graft* or extract* or cataract or refractive or oculoplast* or ophthalmosurg* 92,037
9 #7 or #8 258,017
10 #6 and #9 112,631
11 retrobulbar or peribulbar or sub-tenon's block or sub-tenon's block 806
12 "Nerve Block" or Lidocaine or Mepivacaine or Bupivacaine 19,237
13 (local anaesthe*) or (local anesthe*) 15,573
14 #11 or #12 or #13 25,341
15 #10 and #14 11,101
16 hyaluronidase or hyaluronoglucosaminidase or hyadase or vitrase or Amphadase or wydase or
hyalase or hylenex
533
17 #10 and #14 and #16 230
18 Limit to TRIALS database 207
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1 eye* or Ophthalm* or ocular 578,410
2 cornea* or retin* or scler* or vitre* or iris or pupil or orbit* or chorod* 738,578
3 intraocular or intra-ocular or extraocular or extra-ocular or monocular or oculo* or oculi or optic* 478,576
4 visual* or vision or sight or see* or view* or blind* 2,691,438
5 glaucoma or conjuncti* or uveitis or macula* or oedema or edema or strabismus or squint or
astigmati* or myopi* or hypermetropia or trachoma
436,501
6 1 or 2 or 3 or 4 or 5 3,928,131
7 surg* or operat* 2,516,135
8 transplant* or graft* or extract* or cataract or refractive or oculoplast* or ophthalmosurg* 1,578,347
9 7 or 8 3,810,842
10 6 and 9 724,695
11 exp Ophthalmologic Surgical Procedures/ or exp Cataract Extraction/ 99,847
12 exp Refractive Surgical Procedures/ 54,938
13 exp Corneal Transplantation/ 14,186
14 exp Phacoemulsification/ or exp Lens Implantation, Intraocular/ 13,574
15 11 or 12 or 13 or 14 99,847
16 10 or 15 753,408
17 retrobulbar or peribulbar or sub-tenon's block or subtenon's block 4698
18 local anaesthe* or local anesthe* 38,258
19 17 or 18 42,504
20 exp Anesthesia, Local/ 16,213
21 exp Anesthetics, Local/ 99,177
22 exp Lidocaine/ or exp Nerve Block/ 30,602
23 exp Mepivacaine/ or exp Bupivacaine/ 12,786
24 20 or 21 or 22 or 23 120,407
25 19 or 24 140,352
26 16 and 25 13,782
27 hyaluronidase or hyaluronoglucosaminidase or hyadase or vitrase or Amphadase or wydase or
hyalase or hylenex
10,943
28 exp Hyaluronoglucosaminidase 8216
29 27 or 28 10,943
30 16 and 25 and 29 319
 
31
limit 30 to controlled clinical trial or randomised controlled trial 139
32 (((single adj (blind* or masked)) or double) adj (blind* or masked)).ab. or (((single adj (blind* ormasked)) or double) adj (blind* or masked)).ti. 142,612
33 (randomized or randomly or placebo or trial or (controlled adj study)).ab. or (randomized or
randomly or placebo or trial or (controlled adj study)).ti.
1,054,662
34 32 or 33 1,066,944
35 30 and 34 135
36 31 or 35 155
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1 eye* or Ophthalm* or ocular 714,955
2 cornea* or retin* or scler* or vitre* or iris or pupil or orbit* or chorod* 1,053,140
3 intraocular or intra-ocular or extraocular or extra-ocular or monocular or oculo* or oculi or optic* 503,874
4 visual* or vision or sight or see* or view* or blind* 3,707,107
5 glaucoma or conjuncti* or uveitis or macula* or oedema or edema or strabismus or squint or
astigmati* or myopi* or hypermetropia or trachoma
688,043
6 1 or 2 or 3 or 4 or 5 5,252,878
7 surg* or operat* 4,385,968
8 transplant* or graft* or extract* or cataract or refractive or oculoplast* or ophthalmosurg* 2,208,147
9 7 or 8 6,014,664
10 6 and 9 1,223,645
11 exp eye surgery/ 133,842
12 exp cornea transplantation/ 11,680
13 exp cataract extraction/ or extracapsular cataract extraction/ 43,300
14 exp refractive surgery/ 8947
15 exp lens implant/ 20,733
16 exp eyelid reconstruction/ 5242
17 11 or 12 or 13 or 14 or 15 or 16 138,278
18 10 or 17 1,241,841
19 retrobulbar or peribulbar or sub-tenon's block or subtenon's block 7897
20 local anaesthe* or local anesthe* 80,577
21 19 or 20 87,361
22 exp retrobulbar drug administration/ 1081
23 exp lidocaine/ or exp peribulbar anesthesia/ or exp local anesthetic agent/ or exp bupivacaine/ 228,041
24 exp local anesthesia/ or exp nerve block/ 68,789
25 exp levobupivacaine/ or exp procaine/ 22,051
26 ropivacaine/ or midazolam/ or propofol/ 80,182
27 22 or 23 or 24 or 25 or 26 326,465
28 21 or 27 343,082
29 18 and 28 40,436
30 hyaluronidase or hyaluronoglucosaminidase or hyadase or vitrase or Amphadase or wydase or
hyalase or hylenex
16,613
31 exp recombinant hyaluronidase/ or exp hyaluronidase/ or exp hyaluronoglucosaminidase/ 14,509
32 30 or 31 16,613
33 18 and 28 and 32 709
34 limit 33 to (clinical trial or randomized controlled trial or controlled clinical trial or multicenter study or
phase 1 clinical trial or phase 2 clinical trial or phase 3 clinical trial or phase 4 clinical trial)
199
35 (randomi?ed or randomly or placebo or trial or (controlled adj study)).ab. or (randomi?ed or randomly
or placebo or trial or (controlled adj study)).ti.
1,391,344
36 (((single adj (blind* or masked)) or double) adj (blind* or masked)).ab. or (((single adj (blind* or
masked)) or double) adj (blind* or masked)).ti.
185,195
37 35 or 36 1,408,147
38 33 and 37 199
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1 eye* or Ophthalm* or ocular 476,661
2 cornea* or retin* or scler* or vitre* or iris or pupil or orbit* or chorod* 1,045,927
3 intraocular or intra-ocular or extraocular or extra-ocular or monocular or oculo* or oculi or optic* 1,576,811
4 visual* or vision or sight or see* or view* or blind* 4,121,849
5 glaucoma or conjuncti* or uveitis or macula* or oedema or edema or strabismus or squint or
astigmati* or myopi* or hypermetropia or trachoma
425,695
6 #5 OR #4 OR #3 OR #2 OR #1 6,754,964
7 surg* or operat* 3,423,025
8 transplant* or graft* or extract* or cataract or refractive or oculoplast* or ophthalmosurg* 2,193,730
9 #8 OR #7 5,349,001
10 #9 AND #6 1,005,525
11 (Lens Implantat*) OR (cornea transplantat*) OR (cataract extract*) OR (refractive surg*) OR (exp
eyelid reconstruct*)
26,003
12 #11 OR #10 1,008,989
13 (retrobulbar or peribulbar or sub-tenon's block or subtenon's block) 4057
14 (retrobulbar or peribulbar or sub-tenon's block or sub-tenon's block) 4056
15 (local anaesthe*) OR (local anesthe*) 41,088
16 (lidocaine OR levobupivacaine OR procaine OR ropivacaine OR midazolam OR propofol) OR
TOPIC: (nerve block)
85,921
17 #16 OR #15 OR #14 OR #13 117,842
18 (hyaluronidase or hyaluronoglucosaminidase or hyadase or vitrase or Amphadase or wydase or
hyalase or hylenex) OR TOPIC: (recombinant hyaluronidase)
6294
19 #18 AND #17 AND #12 214
5 Scopus from 1823 to 30 June 2017






1 eye* or Ophthalm* or ocular 1,943,281
2 cornea* or retin* or scler* or vitre* or iris or pupil or orbit* or chorod* 3,136,708
3 intraocular or intra-ocular or extraocular or extra-ocular or monocular or oculo* or oculi or optic 872,852
4 visual* or vision or sight or see* or view* or blind* 13,637,048
5 glaucoma or conjuncti* or uveitis or macula* or oedema or edema or strabismus or squint or
astigmati* or myopi* or hypermetropia or trachoma
1,292,318
6 surg* or operat* 11,977,249
7 transplant* or graft* or extract* or cataract or refractive or oculoplast* or ophthalmosurg* 6,168,543
8 retrobulbar or peribulbar or (sub-tenon's block) or (subtenon's block) 15,268
9 (local anaesthe*) or (local anesthe*) 241,430
10 Lidocaine or (Nerve Block) or Mepivacaine or Bupivacaine 334,730
11 hyaluronidase OR hyaluronoglucosaminidase OR hyadase OR vitrase OR amphadase OR wydase
OR hyalase OR hylenex
28,617
12 #1 or #2 or #3 or #4 or #5 16,812,220
13 #6 or #7 16,339,616
14 #8 or #9 or #10 509,491
15 #11 and #12 and #13 and #14 1,857
6 CINAHL Plus (EBSCOhost) from 1937 to 30 June 2017






1 eye* or Ophthalm* or ocular 62,235
2 cornea* or retin* or scler* or vitre* or iris or pupil or orbit* or chorod* 68,825
3 intraocular or intra-ocular or extraocular or extra-ocular or monocular or oculo* or oculi or optic* 24,333
4 visual* or vision or sight or see* or view* or blind* 426,645
5 glaucoma or conjuncti* or uveitis or macula* or oedema or edema or strabismus or squint or
astigmati* or myopi* or hypermetropia or trachoma
48,062
6 S1 OR S2 OR S3 OR S4 OR S5 547,031
7 surg* or operat* 513,190
8 transplant* or graft* or extract* or cataract or refractive or oculoplast* or ophthalmosurg* 162,110
9 S7 OR S8 625,438
10 S6 AND S9 101,771
11 (MH "Surgery, Eye+") OR (MM "Keratomileusis, Laser in Situ") OR (MM "Eye Enucleation") 13,308
12 (MM "Corneal Transplantation") 1060
13 (MH "Cataract Extraction+") 5140
14 (MM "Phacoemulsification") 848
15 S11 OR S12 OR S13 OR S14 13,308
16 S10 OR S15 104,161
17 retrobulbar or peribulbar or sub-tenon's block or subtenon's block 352
18 local anaesthe* or local anesthe* 10,097
19 S17 OR S18 11,261
20 (MM "Nerve Block") 4680
21 (MM "Anesthesia, Local") OR (MH "Anesthetics, Local+") 14,442
22 S20 OR S21 17,375
23 S19 OR S22 20,462
24 S16 AND S23 2377
25 hyaluronidase or hyaluronoglucosaminidase or hyadase or vitrase or Amphadase or wydase or
hyalase or hylenex
371
26 (MM "Hyaluronidase") 129
27 S25 OR S26 371
28 S16 AND S23 AND S27 40
7 LILACS from 1982 to 30 June 2017






1 eye* or Ophthalm* or ocular or cornea* or retin* or scler* or vitre* or iris or pupil or orbit* or chorod* or
intraocular or intra-ocular or extraocular or extra-ocular or monocular or oculo* or oculi or optic* or
visual* or vision or sight or see* or view* or blind* or glaucoma or conjuncti* or uveitis or macula* or
oedema or edema or strabismus or squint or astigmati* or myopi* or hypermetropia or trachoma
5,238,714
2 surg* or operat* or transplant* or graft* or extract* or cataract or refractive or oculoplast* or
ophthalmosurg*
4,831,015
3 retrobulbar or peribulbar or sub-tenon's block or sub-tenon's block or (local anaesthe*) or (local
anesthe*) or Lidocaine or (Nerve Block) or Mepivacaine or Bupivacaine
320,196
4 hyaluronidase OR hyaluronoglucosaminidase OR hyadase OR vitrase OR amphadase OR wydase OR
hyalase OR hylenex
8146
5 1 and 2 and 3 and 4 and 5 336
8 Data collection form
Cochrane Anaesthesia Review Group
Study Selection, Quality Assessment & Data Extraction Form





RCT/Quasi/CCT¬ (delete as appropriate)Relevant participantsRelevant interventionsRelevant outcomes
¬
Yes / No / Unclear
¬
Yes / No / Unclear
¬
Yes / No / Unclear
¬
Yes / No* / Unclear
¬
* Issue relates to selective reporting when authors may have taken measurements for particular outcomes, but not reported
these within the paper(s). Reviewers should contact trialists for information on possible non-reported outcomes & reasons for
exclusion from publication. Study should be listed in ‘Studies awaiting assessment’ until clarified. If no clarification is received
after three attempts, study should then be excluded. 
¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬
Do not proceed if any of the above answers are ‘No’. If study to be included in ‘Excluded studies’ section of the review,
record below the information to be inserted into ‘Table of excluded studies’.
¬¬
¬
Freehand space for comments on study design and treatment:
References to trial
Check other references identified in searches. If there are further references to this trial link the papers now & list below. All
references to a trial should be linked under one Study ID in RevMan.
Code each paper Author(s) Journal/Conference Proceedings etc Year
A The paper listed above ¬ ¬
B Further papers ¬ ¬
¬ ¬ ¬ ¬




Age (mean, median, range, etc) ¬
Sex of participants (numbers / %, etc) ¬












Process used to prevent foreknowledge of group assignment in a RCT, which should be seen as distinct from masking





Person responsible for participants care Yes / No
Participant Yes / No
Outcome assessor Yes / No
Other (please specify) Yes / No
Intention-to-treat
An intention-to-treat analysis is one in which all the participants in a trial are analysed according to the intervention to which
they were allocated, whether they received it or not.
All participants entering trial ¬
15% or fewer excluded ¬
More than 15% excluded ¬
Not analysed as ‘intention-to-treat’ ¬
Unclear ¬
¬
Were withdrawals described?¬¬¬ Yes¬ ? ¬¬¬¬¬¬¬¬¬¬ ¬¬No ?¬ ¬¬¬¬¬ not clear¬ ?¬¬
Is attrition reported? Yes ? no ?
Total number randomized  
Number in hyaluronidase group 
Number in control group  
Discuss if appropriate and note reasons for attrition
¬
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Outcomes relevant to your review
¬ Reported in paper (circle)
Intraoperative pain Yes / No
Adverse Events Yes / No
















Details if outcome only described
in text
n Mean (SD) nMean
(SD)
¬
  Intraoperative VAS pain
score
(include range)




Outcomes Intervention group (n)
n = number of participants, not number
of events
Control group (n)
n = number of¬ participants, not number
of events





Other information which you feel is relevant to the results
Indicate if: any data were obtained from the primary author; if results were estimated from graphs etc; or calculated by you
using a formula (this should be stated and the formula given). In general if results not reported in paper(s) are obtained this
should be made clear here to be cited in review.











References to other trials
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Did this report include any references to published reports of potentially eligible trials not already identified for this review?
First author Journal / Conference Year of publication
¬ ¬ ¬
     
Did this report include any references to unpublished data from potentially eligible trials not already identified for this







Single centre / Multicentre ¬
Country / Countries ¬
How was participant eligibility defined?¬ ¬
How many people were randomized? ¬
Number of participants in each intervention group ¬
Number of participants who received intended treatment ¬
Number of participants who were analysed ¬
Local anaesthetic Drug dose (s) used ¬
Dose of hyaluronidase ¬
Median (range) length of follow-up reported in this paper (state weeks, months or years or if not stated)¬
Time-points when measurements were taken during the study ¬
Time-points reported in the study ¬
Time-points you are using in RevMan ¬
Trial design ¬
Other ¬
9 Characteristics of excluded studies
Reason for exclusion noted as narrative only:
10 Risk of bias table
Entry
Judgement
Low risk/high risk/unclear risk
Description
1. Random sequence generation    
2. Allocation concealment    
3. Masking of participants and personnel    
4. Masking of outcome assessment    
5. Incomplete outcome data    
6. Selective reporting    
7. Other bias    
233 Use of hyaluronidase as an adjunct to local anaesthetic eye blocks to reduce intraoperative pain in adults
37 / 38
233 Use of hyaluronidase as an adjunct to local anaesthetic eye blocks to reduce intraoperative pain in adults
38 / 38
